Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 1-Year Low – Should You Sell?

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as $18.00 and last traded at $18.05, with a volume of 6643 shares traded. The stock had previously closed at $18.29.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. HC Wainwright reissued a “buy” rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Wedbush reiterated an “outperform” rating and set a $36.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Guggenheim restated a “buy” rating and issued a $84.00 price objective on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Raymond James raised shares of Dianthus Therapeutics to a “moderate buy” rating in a research note on Thursday, December 12th. Finally, TD Cowen started coverage on shares of Dianthus Therapeutics in a report on Friday, December 20th. They issued a “buy” rating on the stock. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $54.33.

Dianthus Therapeutics Stock Performance

The company has a market cap of $638.32 million, a PE ratio of -7.95 and a beta of 1.82. The business’s 50-day moving average is $21.91 and its 200 day moving average is $24.34.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Tuesday, March 11th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.04. The firm had revenue of $1.33 million for the quarter, compared to the consensus estimate of $1.40 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. Equities research analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in DNTH. Quest Partners LLC boosted its position in Dianthus Therapeutics by 112,400.0% during the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock valued at $31,000 after buying an additional 1,124 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in shares of Dianthus Therapeutics by 142.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 165,929 shares of the company’s stock worth $4,543,000 after purchasing an additional 97,362 shares during the period. MetLife Investment Management LLC grew its stake in shares of Dianthus Therapeutics by 129.1% in the third quarter. MetLife Investment Management LLC now owns 13,939 shares of the company’s stock worth $382,000 after purchasing an additional 7,854 shares during the last quarter. Walleye Capital LLC purchased a new position in Dianthus Therapeutics during the 3rd quarter valued at about $821,000. Finally, Braidwell LP increased its holdings in Dianthus Therapeutics by 34.6% during the 3rd quarter. Braidwell LP now owns 493,687 shares of the company’s stock valued at $13,517,000 after purchasing an additional 126,836 shares during the period. Institutional investors own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.